Flavonoid-rich diet slashes type 2 diabetes risk by up to 28%, new study reveals

With an FDA de­ci­sion ex­pect­ed next week for its blood pres­sure drug so­tater­cept, Mer­ck is hop­ing that its bun­dle of ac­qui­si­tions in re­cent years will

Carte­sian Ther­a­peu­tics re­port­ed longer-term re­sults from a mid-stage study of its mR­NA CAR-T ther­a­py for myas­the­nia gravis, sug­gest­ing that the ther­a­py is durable be­yond the